August 8,2024
Xgene Pharmaceutical Announces Positive Topline Results from Phase 2b Trial of XG005 Tablet for Treatment the Symptoms of Osteoarthritis of the Knee
May 08,2024
Xgene Pharmaceutical Pty Ltd. Announced the Enrollment of the First Cohort in the Phase I clinical trial of XG2002 capsules, a novel selective TRPM8 channel blocker.
April 08,2024
Xgene Pharmaceutical Pty Ltd. Announced that XG005 Phase II Clinical Trial of Keen Osteoarthritis in China Has Completed the Enrollment of Target Subjects
March 11,2024
Xgene Pharmaceutical Pty Ltd. Receives HREC’s approval to initiate a First-In-Human (FIH) trial of its innovative analgesic product XG2002
August 23,2023
Xgene Pharmaceutical Inc. Announces Dosing of First Patient in a Phase 2b/3 Trial of XG005 for the Treatment of Pain Following Bunionectomy Surgery.
April 26,2023
Xgene Pharmaceutical Announces Positive Top-Line Results from Phase 1b/2a Trial of Topical Gel XG004 for the Treatment of Osteoarthritis (OA) Pain of the Knee
November 04,2021
Xgene Pharmaceutical secures $40m in Series C
September 22,2021
Xgene Pharmaceuticals Co. Ltd.and RaQualia Pharma Inc.have entered into a licensing agreement for a novel TRPM8 blocker discovered by RaQualia Pharma
April 22,2020
NDA Application of XG005 will follow a 505(B)(1) regulatory pathway
May 4, 2019
XGene Pharmaceutical Closed the B Plus
Round Financing
October 25, 2018
XGene Pharmaceutical Closed US$20 Million B Round Financing